Abstract: The present invention relates to a method for screening a compound for Parkinson's disease treatment, comprising contacting a cell having a DJ-1 gene containing a c.192G>C mutation with a compound of interest, and testing whether said compound of interest prevents skipping of exon 3 of said DJ-1 gene, thereby identifying said compound as candidate for Parkinson's disease treatment. The present invention further relates to a compound which prevents skipping of exon 3 of the DJ-1 gene for use in a method of treatment of Parkinson's disease. The present invention further relates to a pharmaceutical composition comprising one or more compounds which prevents skipping of exon 3 of the DJ-1 gene for use in a method of treatment of Parkinson's disease.

Abstract: The present invention relates to a method of treating movement disorders of a living being, a method of treating refractory gait disturbances of a human Parkinson's disease patient being affected by gait disturbances, and an apparatus for deep brain stimulation (DBS) of a living being affected by movement disorders.

Abstract: The present invention relates to a method of treating movement disorders of a living being, a method of treating refractory gait disturbances of a human Parkinson's disease patient being affected by gait disturbances, and an apparatus for deep brain stimulation (DBS) of a living being affected by movement disorders.

Abstract: The present invention relates to a method for diagnosing Parkinson's disease in a human being; nucleic acid molecules used in this method; a nucleic acid molecule which encodes a human Omi/HtrA2 protein which has a genetic modification at amino acid position 141 and/or 399 compared with the wild type, and for corresponding segments thereof; a host, preferably a transgenic non-human mammal, into which such a nucleic acid molecule has been introduced; a (poly)peptide which is encoded by such a nucleic acid molecule; a method for finding substances which bind to Omi/HtrA2 protein which is genetically modified compared with the wild type; a substance found with the aid of this method, and a preferably pharmaceutical composition which comprises such a substance. This invention additionally relates to a kit which comprises at least one of the aforementioned nucleic acid molecules.